The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy

Dong H. Shin*, Michael S. McCracken, Rick E. Bendel, Robert Pearlman, Mark S. Juzych, Bret A. Hughes, Laura L. Schulz, Chaesik Kim, Nam H. Baek

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Objective: To assess the efficacy of latanoprost additive therapy in patients with intraocular pressure (IOP) out of control while taking maximum- tolerated medications and to determine whether pilocarpine therapy has a dose-dependent adverse effect on the efficacy of latanoprost therapy. Design: Noncomparative case series. Participants: Sixty-one eyes of 61 patients with chronic glaucoma with IOP out of control while receiving maximum-tolerated medications were treated with latanoprost additive therapy on a compassionate basis. Main Outcome Measures: Follow-up was up to 22 months with a mean of 13.9 ± 5.7 months. Kaplan-Meier survival analysis with Mantel-Cox log-rank test was performed to determine the overall success of latanoprost additive therapy and to compare the success rates of high-dose pilocarpine, low-dose pilocarpine, and no pilocarpine therapies. The criterion for success was avoiding glaucoma surgery with IOP decrease of 20% or greater and final IOP less than 22 mmHg. The IOP change and its significance for patients satisfying and failing the criterion for success also were determined to assess the latanoprost additive therapy. In addition, a number of pretreatment variables, including pilocarpine therapy, were analyzed for a significant effect on the efficacy of latanoprost additive therapy using Cox proportional hazards regression analysis. Results: Latanoprost additive therapy significantly lowered mean IOP by 3.9 ± 5.5 mmHg at 3 months and by 3.5 ± 5.8 mmHg at 12 months. The cumulative success rate of the latanoprost additive therapy was 70% at 1 month, 42% at 3 months, 40% at 6 months, and 30% at 12 months. Of the variables studied, only increased number of previous incisional glaucoma surgeries and IOP greater than 24 mmHg before latanoprost additive therapy were significant prognostic factors for failure of latanoprost additive therapy. Pilocarpine therapy in any dose had no significant effect. Conclusion: This study supports a trial of latanoprost additive therapy before glaucoma surgery in patients with IOP out of control while receiving maximum-tolerated medications irrespective of pilocarpine therapy and the pilocarpine dosage, especially when the number of previous incisional glaucoma surgery is less than three and the IOP is less than 25 mmHg.

Original languageEnglish (US)
Pages (from-to)386-390
Number of pages5
JournalOphthalmology
Volume106
Issue number2
DOIs
StatePublished - Feb 1 1999

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy'. Together they form a unique fingerprint.

Cite this